Article
Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).
Clinical lung cancer - 1 Nov 2020
Miura Satoru, Yamanaka Takeharu, Kato Terufumi, Ikeda Satoshi, Horinouchi Hidehito, Ichihara Eiki, Kanazu Masaki, Takiguchi Yuichi, Tanaka Kentaro, Goto Yasuhiro, Sata Masafumi, Hagiwara Koichi, Okamoto Hiroaki, Tanaka Hiroshi
Abstract excerpt
We describe the treatment rationale and design of our randomized phase III study, the ACHILLES trial (Japan Registry of Clinical Trials: jRCTs031180175). The aim of this study is to investigate the superiority of afatinib over chemotherapy as first-line treatment in patients with advanced nonsquamous non-small-cell lung cancer with sensitizing uncommon or compound epidermal growth factor receptor (EGFR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.